NCT04580836 2024-10-26
MRI-Guided Radiation Therapy for the Treatment of Early-Stage Kidney Cancer, the MRI-MARK Trial
M.D. Anderson Cancer Center
Phase 2 Withdrawn
Clinical Trials
17 trialsNCT02232646 2023-11-14
A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies
Sumitomo Pharma America, Inc.
Phase 2 Withdrawn
NCT04603365 2023-05-17
Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn
NCT05263609 2022-08-02
Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib
University of Oklahoma
Phase 2 Withdrawn
NCT03035630 2022-02-15
Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma
Hoosier Cancer Research Network
Phase 2 Withdrawn
NCT04262375 2020-11-17
DOMINATION
University Health Network, Toronto
Phase 2 Withdrawn
NCT03323710 2019-01-09
Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma
Military Institute od Medicine National Research Institute
Phase 2 Withdrawn
NCT03226236 2018-11-13
RENALVax-2
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Withdrawn
NCT02763761 2018-10-09
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT03149159 2018-06-18
Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab
Medical University of South Carolina
Phase 2 Withdrawn
NCT02962804 2018-03-05
Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)
University of Kansas Medical Center
Phase 2 Withdrawn
NCT00025519 2013-07-11
Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer
Fox Chase Cancer Center
Phase 2 Withdrawn
NCT00040989 2013-07-10
BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT01834183 2013-06-19
Tivozanib + Gemcitabine in Metastatic RCC
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT01616186 2013-04-08
Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)
University of California, San Francisco
Phase 2 Withdrawn
NCT00311545 2013-02-20
S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer
SWOG Cancer Research Network
Phase 2 Withdrawn
NCT01070186 2012-07-31
Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn